RU2010113997A - Тиролиберин для терапевтического применения - Google Patents
Тиролиберин для терапевтического применения Download PDFInfo
- Publication number
- RU2010113997A RU2010113997A RU2010113997/15A RU2010113997A RU2010113997A RU 2010113997 A RU2010113997 A RU 2010113997A RU 2010113997/15 A RU2010113997/15 A RU 2010113997/15A RU 2010113997 A RU2010113997 A RU 2010113997A RU 2010113997 A RU2010113997 A RU 2010113997A
- Authority
- RU
- Russia
- Prior art keywords
- diseases
- disease
- pharmaceutical composition
- peptide
- fibrosis
- Prior art date
Links
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 title claims abstract 5
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 title 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 10
- 239000000203 mixture Substances 0.000 claims abstract 7
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract 5
- 208000035473 Communicable disease Diseases 0.000 claims abstract 5
- 206010016654 Fibrosis Diseases 0.000 claims abstract 5
- 208000019693 Lung disease Diseases 0.000 claims abstract 5
- 201000011510 cancer Diseases 0.000 claims abstract 5
- 230000004761 fibrosis Effects 0.000 claims abstract 5
- 208000019622 heart disease Diseases 0.000 claims abstract 5
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 5
- 230000030833 cell death Effects 0.000 claims abstract 4
- 239000007788 liquid Substances 0.000 claims abstract 4
- 238000011282 treatment Methods 0.000 claims abstract 3
- 208000019553 vascular disease Diseases 0.000 claims abstract 3
- 208000030507 AIDS Diseases 0.000 claims abstract 2
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 claims abstract 2
- 208000007788 Acute Liver Failure Diseases 0.000 claims abstract 2
- 206010000804 Acute hepatic failure Diseases 0.000 claims abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims abstract 2
- 208000026372 Congenital cystic kidney disease Diseases 0.000 claims abstract 2
- 206010025327 Lymphopenia Diseases 0.000 claims abstract 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims abstract 2
- 206010038540 Renal tubular necrosis Diseases 0.000 claims abstract 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims abstract 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims abstract 2
- 208000006011 Stroke Diseases 0.000 claims abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract 2
- 231100000836 acute liver failure Toxicity 0.000 claims abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract 2
- 210000004204 blood vessel Anatomy 0.000 claims abstract 2
- 239000000872 buffer Substances 0.000 claims abstract 2
- 239000007853 buffer solution Substances 0.000 claims abstract 2
- 239000002577 cryoprotective agent Substances 0.000 claims abstract 2
- 230000007812 deficiency Effects 0.000 claims abstract 2
- 239000003085 diluting agent Substances 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 206010015037 epilepsy Diseases 0.000 claims abstract 2
- 210000002919 epithelial cell Anatomy 0.000 claims abstract 2
- 102000010705 glucose-6-phosphate dehydrogenase activity proteins Human genes 0.000 claims abstract 2
- 108040005050 glucose-6-phosphate dehydrogenase activity proteins Proteins 0.000 claims abstract 2
- 208000015181 infectious disease Diseases 0.000 claims abstract 2
- 208000000509 infertility Diseases 0.000 claims abstract 2
- 230000036512 infertility Effects 0.000 claims abstract 2
- 231100000535 infertility Toxicity 0.000 claims abstract 2
- 238000001990 intravenous administration Methods 0.000 claims abstract 2
- 230000000302 ischemic effect Effects 0.000 claims abstract 2
- 210000003734 kidney Anatomy 0.000 claims abstract 2
- -1 lyoprotector Substances 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 208000010125 myocardial infarction Diseases 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims abstract 2
- 238000011321 prophylaxis Methods 0.000 claims abstract 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims abstract 2
- 241000712461 unidentified influenza virus Species 0.000 claims abstract 2
- 210000004251 human milk Anatomy 0.000 claims 2
- 235000020256 human milk Nutrition 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
Abstract
1. Применение пептида Pyr-His-Pro-NH2 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов. ! 2. Применение пептида по п.1, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов выбраны из СПИДа, болезни Альцгеймера, бокового амиотрофического склероза, ишемического повреждения почки, пигментного ретинита, эпилепсии, апластической анемии, миелодиспластического синдрома, CD4+ T-клеточной лимфоцитопении, дефицита Г6ФДГ, инфаркта миокарда, инсульта, поликистозной почки, острой печеночной недостаточности, острого тубулярного некроза, бесплодия, индуцированной Streptococcus pneumoniae гибели эпителиальных клеток и индуцированной вирусом гриппа гибели клеток. ! 3. Применение пептида по п.1 или 2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста. ! 4. Применение пептида по п.1 или 2 для получения лиофилизированного состава или буферного жидкого состава. ! 5. Фармацевтическая композиция, содержащая пептид Pyr-His-Pro-NH2, по меньшей мере, совместно с одним фармацевтически приемлемым носителем, криопротектором, лиопротектором, эксципиентом и/или разбавителем. ! 6. Фармацевтическая композиция по п.5 в форме лиофилизата или жидкого буферного раствора. ! 7. Фармацевтическая композиция по п.5 или 6, пригодная для внутривенного введения, перорального введения или для введения посредство
Claims (9)
1. Применение пептида Pyr-His-Pro-NH2 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов.
2. Применение пептида по п.1, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов выбраны из СПИДа, болезни Альцгеймера, бокового амиотрофического склероза, ишемического повреждения почки, пигментного ретинита, эпилепсии, апластической анемии, миелодиспластического синдрома, CD4+ T-клеточной лимфоцитопении, дефицита Г6ФДГ, инфаркта миокарда, инсульта, поликистозной почки, острой печеночной недостаточности, острого тубулярного некроза, бесплодия, индуцированной Streptococcus pneumoniae гибели эпителиальных клеток и индуцированной вирусом гриппа гибели клеток.
3. Применение пептида по п.1 или 2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
4. Применение пептида по п.1 или 2 для получения лиофилизированного состава или буферного жидкого состава.
5. Фармацевтическая композиция, содержащая пептид Pyr-His-Pro-NH2, по меньшей мере, совместно с одним фармацевтически приемлемым носителем, криопротектором, лиопротектором, эксципиентом и/или разбавителем.
6. Фармацевтическая композиция по п.5 в форме лиофилизата или жидкого буферного раствора.
7. Фармацевтическая композиция по п.5 или 6, пригодная для внутривенного введения, перорального введения или для введения посредством ингаляции.
8. Фармацевтическая композиция по п.5 или 6 в форме состава искусственного материнского молока или заменителя материнского молока, пригодная для пероральной доставки новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
9. Фармацевтическая композиция по п.5 или 6, пригодная для лечения и/или профилактики злокачественной опухоли, аутоиммунного заболевания, фиброза, воспалительного заболевания, инфекционного заболевания, заболевания легких, заболевания сердца и сосудов.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07017751 | 2007-09-11 | ||
EP07017751.4 | 2007-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2010113997A true RU2010113997A (ru) | 2011-10-20 |
Family
ID=40243834
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010113979/15A RU2010113979A (ru) | 2007-09-11 | 2008-09-09 | Применение bubuc и необязательно eaa-marti (26-35) в качестве терапевтического средства для лечения инфекций hcmv |
RU2010114044/15A RU2010114044A (ru) | 2007-09-11 | 2008-09-09 | Применение белка полосы 3 (824-829) и/или фактора ингибирования высвобождения меланотропина в качестве терапевтического средства при лечении инфекции pseudomonas aeruginosa |
RU2010113997/15A RU2010113997A (ru) | 2007-09-11 | 2008-09-09 | Тиролиберин для терапевтического применения |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010113979/15A RU2010113979A (ru) | 2007-09-11 | 2008-09-09 | Применение bubuc и необязательно eaa-marti (26-35) в качестве терапевтического средства для лечения инфекций hcmv |
RU2010114044/15A RU2010114044A (ru) | 2007-09-11 | 2008-09-09 | Применение белка полосы 3 (824-829) и/или фактора ингибирования высвобождения меланотропина в качестве терапевтического средства при лечении инфекции pseudomonas aeruginosa |
Country Status (8)
Country | Link |
---|---|
US (3) | US20100210568A1 (ru) |
EP (3) | EP2200629A1 (ru) |
JP (3) | JP2010539064A (ru) |
KR (3) | KR20100061679A (ru) |
AU (3) | AU2008306141A1 (ru) |
CA (3) | CA2699113A1 (ru) |
RU (3) | RU2010113979A (ru) |
WO (13) | WO2009043478A2 (ru) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2282847B1 (en) | 2008-05-22 | 2015-09-23 | Ethicon, Inc. | Process for coating a porous substrate with a coating liquid |
WO2010077591A2 (en) | 2008-12-09 | 2010-07-08 | Smith & Nephew, Inc. | Tissue repair assembly |
EP3305314B1 (en) * | 2010-05-21 | 2019-07-03 | Cytogel Pharma, LLC | Peptide for use in treating neurogenic inflammation |
CN103732618B (zh) | 2011-06-10 | 2018-10-09 | 韩美科学株式会社 | 新型泌酸调节肽衍生物和包含该泌酸调节肽衍生物的用于治疗肥胖的药物组合物 |
SI2721062T1 (sl) | 2011-06-17 | 2019-03-29 | Hanmi Science Co., Ltd. | Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega |
US9149511B2 (en) | 2011-06-30 | 2015-10-06 | Ethicon, Inc. | Procoagulant peptides and their derivatives and uses therefor |
KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
MY197849A (en) | 2012-11-06 | 2023-07-20 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9393264B2 (en) * | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9750787B2 (en) * | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
US10975121B2 (en) | 2017-06-24 | 2021-04-13 | Cytogel Pharma, Llc | Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof |
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
CN109867860A (zh) * | 2019-02-12 | 2019-06-11 | 青岛科技大学 | 一种具有良好光热稳定性的阻燃聚丙烯材料及其制备方法 |
BR112021020287A2 (pt) * | 2019-04-11 | 2021-12-14 | Biohaven Pharm Holding Co Ltd | Formulação para distribuição oral de proteínas, peptídeos e pequenas moléculas com pouca permeabilidade |
CN111187778B (zh) * | 2020-02-10 | 2021-08-24 | 济南大学 | 小麦耐盐基因TaFLZ2及其应用 |
RU2738679C1 (ru) * | 2020-06-26 | 2020-12-15 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ лечения лимфангиом |
US20240174728A1 (en) * | 2021-01-22 | 2024-05-30 | Shenzhen Turier Biotech Co., Ltd. | A use of a polypeptide compound in the preparation of drugs for preventing or treating inflammatory bowel diseases and related intestinal fibrosis |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3795738A (en) * | 1972-12-26 | 1974-03-05 | Abbott Lab | Use of l-propyl l-leucyl glycine amide to treat parkinson's disease |
US4125605A (en) * | 1977-10-19 | 1978-11-14 | The United States Government | Method of employing oral TRH |
FR2488253A1 (fr) * | 1980-08-08 | 1982-02-12 | Roques Bernard | Nouveaux peptides et leur application en therapeutique |
DE3403427A1 (de) * | 1984-02-01 | 1985-08-01 | Degussa Ag, 6000 Frankfurt | Verfahren zur herstellung von 1,4-butandial |
US5118670A (en) * | 1988-12-14 | 1992-06-02 | Massachusetts Institute Of Technology | Process and composition for increasing brain dopamine release |
DE69128283T2 (de) | 1991-08-12 | 1998-03-19 | Nestle Sa | Nahrungsmittelzusammensetzung |
US5411943A (en) * | 1992-02-25 | 1995-05-02 | Biomeasure, Inc. | Hepatoma treatment with somatostatin analogs |
US5403824A (en) * | 1993-03-19 | 1995-04-04 | The Procter & Gamble Company | Methods for the treatment of osteoporosis |
US5744492A (en) * | 1993-09-17 | 1998-04-28 | United States Of America | Method for inhibiting angiogenesis |
WO1995016032A1 (en) * | 1993-12-09 | 1995-06-15 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | ANTISENSE NUCLEIC ACID FOR THE TREATMENT OF DISEASES IN WHICH EXPRESSION OF bFGF, PDGF-A OR PDGF-B PLAYS A PATHOGENIC ROLE |
WO1995029193A2 (en) * | 1994-04-22 | 1995-11-02 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services | Melanoma antigens |
AUPM885894A0 (en) * | 1994-10-18 | 1994-11-10 | University Of Newcastle Research Associates Limited, The | Therapeutic molecules |
US6124262A (en) * | 1995-03-17 | 2000-09-26 | The Regents Of The University Of California | Compositions and methods for reducing adhesiveness of defective red blood cells |
EP0761204B1 (fr) * | 1995-09-07 | 1998-04-15 | L'oreal | Utilisation d'un extrait d'une bactérie filamenteuse non photosynthétique et composition le contenant |
WO1997026853A2 (en) * | 1996-01-24 | 1997-07-31 | Synaptic Pharmaceutical Corporation | Dna encoding galanin galr2 receptors and uses thereof |
EA000900B1 (ru) | 1996-02-19 | 2000-06-26 | Никомед Имеджинг Ас | Термически стабилизированный контрастный агент |
US5861483A (en) * | 1996-04-03 | 1999-01-19 | Pro-Neuron, Inc. | Inhibitor of stem cell proliferation and uses thereof |
TW360501B (en) | 1996-06-27 | 1999-06-11 | Nestle Sa | Dietetically balanced milk product |
EP0918455B1 (en) * | 1996-07-24 | 2003-04-16 | Neurotargets Limited | Use of galanin to repair nerve damage |
ES2359031T3 (es) * | 1996-08-08 | 2011-05-17 | Amylin Pharmaceuticals, Inc. | Composición farmacéutica que comprende un péptido de exendina-4. |
DE69608801T2 (de) | 1996-09-24 | 2000-10-12 | Nestle Sa | Milchaustauschprodukt und Verfahren zu dessen Herstellung |
GB9704174D0 (en) * | 1997-02-28 | 1997-04-16 | Univ Birmingham | Agent for medical treatment |
US6191103B1 (en) * | 1997-12-05 | 2001-02-20 | The Regents Of The University Of California | Methods for enhancing thrombolysis in a mammal |
KR20010033601A (ko) * | 1997-12-24 | 2001-04-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 폴리펩티드, 그의 제법 및 용도 |
EP1291022A1 (en) * | 1998-07-30 | 2003-03-12 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Methods of using lanreotide, a somatostatin analogue |
ES2226466T3 (es) | 1998-11-24 | 2005-03-16 | Societe Des Produits Nestle S.A. | Procedimiento de preparacion de una composicion proteinica y de una formula infantil que la contiene. |
EP1658856B1 (en) * | 1999-01-14 | 2010-03-17 | Amylin Pharmaceuticals, Inc. | Exendins for glucagon suppression |
US20040013641A1 (en) * | 1999-04-15 | 2004-01-22 | Monash University | Disease prevention by reactivation of the thymus |
CA2375148A1 (en) * | 1999-06-04 | 2000-12-14 | Novo Nordisk A/S | Compositions for the treatment of the catabolic state of prolonged critical illness |
WO2001002428A1 (fr) * | 1999-06-30 | 2001-01-11 | Takeda Chemical Industries, Ltd. | Procede de preparation de derives de lh-rh |
WO2001051078A1 (en) * | 2000-01-10 | 2001-07-19 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia |
AU2001257129A1 (en) * | 2000-04-21 | 2001-11-07 | Advanced Research And Technology Institute, Inc. | Novel pharmacotherapeutic process and composition for central nervous system disorders |
US20010053764A1 (en) * | 2000-05-12 | 2001-12-20 | Sims John E. | Interleukin-1 inhibitors in the treatment of diseases |
DE60139399D1 (de) * | 2000-06-21 | 2009-09-10 | Takeda Pharmaceutical | Gpr8 ligand und dafuer kodierende dna |
CN1283314C (zh) * | 2000-08-31 | 2006-11-08 | 盐野义制药株式会社 | 抗帕金森氏病药 |
US8633150B2 (en) * | 2001-05-16 | 2014-01-21 | Tni Biotech, Inc. | Methods for inducing sustained immune response |
EP1427438A2 (en) * | 2001-09-03 | 2004-06-16 | The University of Bristol | Inflammation modulatory compound comprising an endomorphin |
GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
EP1314357B1 (en) | 2001-11-23 | 2007-05-23 | Société des Produits Nestlé S.A. | Process for the preparation of milk powders and concentrated milk products |
AU2002360453C1 (en) * | 2001-11-26 | 2009-06-18 | The Brigham And Women's Hospital, Inc. | Methods for treating autoimmune disorders, and reagents related thereto |
US7105489B2 (en) * | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
US20050209142A1 (en) * | 2002-11-20 | 2005-09-22 | Goran Bertilsson | Compounds and methods for increasing neurogenesis |
JP2006514035A (ja) * | 2002-12-17 | 2006-04-27 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 心不整脈の予防および治療 |
US7790681B2 (en) * | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
AU2004213019B2 (en) * | 2003-02-19 | 2010-06-10 | University Of Rochester | Treatment of pain through expression of opioid receptors |
US7947280B2 (en) * | 2003-05-22 | 2011-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Apelin and uses thereof |
US7494979B2 (en) * | 2003-06-13 | 2009-02-24 | Ironwood Pharmaceuticals, Inc. | Method for treating congestive heart failure and other disorders |
US20050130893A1 (en) * | 2003-09-30 | 2005-06-16 | Joan Smith-Sonneborn | Use of opioids in prevention of and recovery from a stress-induced crash in blood pressure |
CA2546843C (en) * | 2003-11-20 | 2015-01-06 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
US7829526B2 (en) * | 2004-04-02 | 2010-11-09 | Japan Science And Technology Agency | Cardioinhibitory/antihypertensive novel endogenous physiologically active peptide |
JP5064212B2 (ja) * | 2004-05-05 | 2012-10-31 | ヴァロリザーシヨン−ルシェルシュ,ソシエテ・アン・コマンディット | インターロイキン−1受容体アンタゴニスト、組成物、及び治療方法 |
US7462595B2 (en) * | 2004-09-17 | 2008-12-09 | Prange Jr Arthur Jergen | Methods for treating cancer-related fatigue |
CA2584806C (en) * | 2004-11-01 | 2014-06-17 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
NZ564360A (en) * | 2005-06-17 | 2011-03-31 | Mannkind Corp | Immunogenic product comprising a nucleic acid capable of expressing a PRAME epitope and a PSMA epitope and a peptide composition |
JPWO2007072980A1 (ja) * | 2005-12-20 | 2009-06-04 | 武田薬品工業株式会社 | アペリンの新規用途 |
WO2007082726A2 (de) * | 2006-01-17 | 2007-07-26 | Medigene Ag | Fliessfähige leuprolid-haltige zusammensetzung zur behandlung von entzündungsvermittelten neurodegenerativen erkrankungen |
JP5678359B2 (ja) | 2006-03-10 | 2015-03-04 | ラボスイス アーゲー | 物質を可溶化、分散、および安定化させる方法とその方法により製造される生成物とその使用 |
UA22357U (en) * | 2006-10-25 | 2007-04-25 | Inst Surgery Transplantation | Method for treatment of pancreatic pseudocyst and of parapancreatic liquid accumulation |
WO2008143151A1 (ja) * | 2007-05-11 | 2008-11-27 | Proteinexpress Co., Ltd. | サリューシンをターゲットとする動脈硬化性疾患の治療剤及び検出薬 |
-
2008
- 2008-09-09 WO PCT/EP2008/007705 patent/WO2009043478A2/en active Application Filing
- 2008-09-09 KR KR1020107005663A patent/KR20100061679A/ko not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007813 patent/WO2009046823A1/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007743 patent/WO2009040034A2/en active Application Filing
- 2008-09-09 KR KR1020107005594A patent/KR20100058550A/ko not_active Application Discontinuation
- 2008-09-09 RU RU2010113979/15A patent/RU2010113979A/ru not_active Application Discontinuation
- 2008-09-09 EP EP08802586A patent/EP2200629A1/en not_active Withdrawn
- 2008-09-09 CA CA2699113A patent/CA2699113A1/en not_active Abandoned
- 2008-09-09 AU AU2008306141A patent/AU2008306141A1/en not_active Abandoned
- 2008-09-09 EP EP08802238A patent/EP2197470A2/en not_active Withdrawn
- 2008-09-09 KR KR1020107005612A patent/KR20100069651A/ko not_active Application Discontinuation
- 2008-09-09 US US12/677,816 patent/US20100210568A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/008005 patent/WO2009040086A2/en active Application Filing
- 2008-09-09 CA CA2699065A patent/CA2699065A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007677 patent/WO2009033739A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/008112 patent/WO2009043529A1/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007540 patent/WO2009039992A2/en active Application Filing
- 2008-09-09 CA CA2698690A patent/CA2698690A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007939 patent/WO2009040068A2/en active Application Filing
- 2008-09-09 EP EP08802097A patent/EP2187910A2/en not_active Withdrawn
- 2008-09-09 RU RU2010114044/15A patent/RU2010114044A/ru not_active Application Discontinuation
- 2008-09-09 JP JP2010523437A patent/JP2010539064A/ja active Pending
- 2008-09-09 AU AU2008303954A patent/AU2008303954A1/en not_active Abandoned
- 2008-09-09 JP JP2010523372A patent/JP2010538999A/ja active Pending
- 2008-09-09 WO PCT/EP2008/007961 patent/WO2009033777A1/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007852 patent/WO2009033756A2/en active Application Filing
- 2008-09-09 US US12/676,950 patent/US20100204153A1/en not_active Abandoned
- 2008-09-09 JP JP2010523405A patent/JP2010539032A/ja active Pending
- 2008-09-09 WO PCT/EP2008/008025 patent/WO2009046859A2/en active Application Filing
- 2008-09-09 AU AU2008306190A patent/AU2008306190A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007488 patent/WO2009033687A1/en active Application Filing
- 2008-09-09 US US12/677,286 patent/US20100210561A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007678 patent/WO2009033740A2/en active Application Filing
- 2008-09-09 RU RU2010113997/15A patent/RU2010113997A/ru not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2010113997A (ru) | Тиролиберин для терапевтического применения | |
RU2010114043A (ru) | Применение бета-меланотропина в качестве терапевтического средства, например, для лечения спид или болезни альцгеймера | |
RU2010114021A (ru) | Субстанция р и тиролиберин для терапевтического применения | |
RU2010114015A (ru) | Применение пептида в качестве терапевтического средства | |
RU2010113982A (ru) | Применение пептида в качестве терапевтического средства | |
RU2010114054A (ru) | Применение пептида в качестве терапевтического средства | |
RU2010114030A (ru) | Применение пептида в качестве терапевтического средства | |
RU2010114051A (ru) | Применение grf-1(1-29) и кортиколиберина в качестве терапевтических средств | |
RU2010114047A (ru) | Применение нейропептида af человека в качестве терапевтического средства | |
RU2010114002A (ru) | Применение фактора ингибирования высвобождения меланотропина в качестве терапевтического средства при лечении инфекции pseudomonas aeruginosa | |
RU2010113974A (ru) | Применение противовоспалительного пептида-1 в качестве терапевтического средства | |
RU2010114007A (ru) | Применение комбинации пептидов cart в качестве терапевтического средства | |
RU2010113999A (ru) | Применение секретина и необязательно уродилатина в качестве терапевтических средств | |
RU2010113992A (ru) | Применение урокортина и кортиколиберина в качестве терапевтических средств | |
RU2010114023A (ru) | ПРИМЕНЕНИЕ ПЕПТИДА Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu-OH В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА | |
RU2010114019A (ru) | Минигастрин в качестве терапевтического средства | |
RU2010113984A (ru) | Применение врр-в в качестве терапевтического средства | |
RU2010114062A (ru) | ПРИМЕНЕНИЕ ПЕПТИДА Pro-Gly-Thr-Cys-Glu-Ile-Cys-Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА | |
RU2010114035A (ru) | Применение rfrp индивидуально или в комбинации с нейрокинином в в качестве терапевтического средства | |
RU2010114037A (ru) | Применение белка полосы 3 и расар-27 в качестве терапевтического средства | |
RU2010114060A (ru) | Применение пептида в качестве терапевтического средства |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20110912 |